Back
ARS Pharmaceuticals Faces Securities Class Action Over Neffy CVS Caremark Coverage Delay

ARS Pharmaceuticals Faces Securities Class Action Over Neffy CVS Caremark Coverage Delay

Investors who bought SPRY shares from March 9 to June 24, 2026 have until Oct. 5, 2026 to seek lead-plaintiff status after a delay in broader neffy coverage pushed a key decision into 2027.

Fact Check
The Schall firm's own case page, the SBS Law PR Newswire notice, and the DJS Law Group Business Wire release all state the identical proposed class period of May 11, 2026 to July 23, 2026 and lead plaintiff deadline of September 28, 2026. Robbins LLP independently confirms the same class period. The consistency across the originating firm and multiple independent firms strongly supports the claim.
Summary

ARS Pharmaceuticals, Inc. is facing a proposed securities class action on behalf of investors who bought SPRY shares between March 9, 2026 and June 24, 2026, with an Oct. 5, 2026 deadline to seek appointment as lead plaintiff. The complaint alleges the company made overly positive statements while concealing adverse facts about the expected timeline for expanded insurance coverage of neffy through CVS Caremark. After the market closed on June 24, 2026, ARS said it had not obtained the broader coverage by its guided July 1, 2026 deadline and that CVS Caremark had reserved its decision until January 2027, leaving neffy without expanded coverage for the summer and back-to-school allergy seasons. SPRY shares fell from $10.54 on June 24, 2026 to $8.02 on June 25, 2026, a drop of more than 23.9%, according to the complaint.

Terms & Concepts
  • securities class action: A lawsuit brought on behalf of a group of investors who claim they were harmed by misleading statements or omitted information affecting a company's stock.
  • lead plaintiff: The investor chosen by the court to represent the proposed class and help direct the litigation.